亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial

贝里穆马布 医学 美罗华 内科学 安慰剂 临床试验 系统性红斑狼疮 免疫学 随机对照试验 疾病 肿瘤科 B细胞激活因子 抗体 病理 B细胞 替代医学 淋巴瘤
作者
Muhammad Shipa,Liliana Ribeiro Santos,Dao X. Nguyen,Andrew Embleton-Thirsk,Mariea Parvaz,Lauren L Heptinstall,Ruth J. Pepper,David Isenberg,Caroline Gordon,Michael R. Ehrenstein
出处
期刊:The Lancet Rheumatology [Elsevier BV]
卷期号:5 (1): e24-e35 被引量:23
标识
DOI:10.1016/s2665-9913(22)00332-0
摘要

Systemic lupus erythematosus (SLE) is a complex autoimmune disease associated with widespread immune dysregulation and diverse clinical features. Immune abnormalities might be differentially associated with specific organ involvement or response to targeted therapies. We aimed to identify biomarkers of response to belimumab after rituximab to facilitate a personalised approach to therapy.In this exploratory analysis of a randomised controlled trial (BEAT-LUPUS), we investigated immune profiles of patients with SLE recruited to the 52-week clinical trial, which tested the combination of rituximab plus belimumab versus rituximab plus placebo. We used machine learning and conventional statistics to investigate relevant laboratory and clinical biomarkers associated with major clinical response. BEAT LUPUS is registered at ISRCTN, 47873003, and is now complete.Between Feb 2, 2017, and March 28, 2019, 52 patients were recruited to BEAT-LUPUS, of whom 44 provided clinical data at week 52 and were included in this analysis. 21 (48%) of 44 participants were in the belimumab group (mean age 39·5 years [SD 12·1]; 17 [81%] were female, four [19%] were male, 13 [62%] were White) and 23 (52%) were in the placebo group (mean age 42·1 years [SD 10·5]; 21 [91%] were female, two [9%] were male, 16 [70%] were White). Ten (48%) of 21 participants who received belimumab after rituximab and eight (35%) of 23 who received placebo after rituximab had a major clinical response at 52 weeks (between-group difference of 13% [95% CI -15 to 38]). We found a predictive association between baseline serum IgA2 anti-double stranded DNA (dsDNA) antibody concentrations and clinical response to belimumab after rituximab, with a between-group difference in major clinical response of 48% (95% CI 10 to 70) in patients with elevated baseline serum IgA2 anti-dsDNA antibody concentrations. Moreover, among those who had a major clinical response, serum IgA2 anti-dsDNA antibody concentrations significantly decreased from baseline only in the belimumab group. Increased circulating IgA2 (but not total) plasmablast numbers, and T follicular helper cell numbers predicted clinical response and were both reduced only in patients who responded to belimumab after rituximab. Serum IgA2 anti-dsDNA antibody concentrations were also associated with active renal disease, whereas serum IgA1 anti-dsDNA antibody and IFN-α concentrations were associated with mucocutaneous disease activity but did not predict response to B-cell targeted therapy. Patients with a high baseline serum interleukin-6 concentration were less likely to have a major clinical response, irrespective of therapy.This exploratory study revealed the presence of distinct molecular networks associated with renal and mucocutaneous involvement, and response to B-cell-targeted therapies, which, if confirmed, could guide precision targeting of advanced therapies for this heterogenous disease.Versus Arthritis, UCLH Biomedical Research Centre, LUPUS UK, and GSK.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yasiraziz完成签到,获得积分10
36秒前
36秒前
yasiraziz发布了新的文献求助10
42秒前
迷人的晓灵完成签到,获得积分10
46秒前
无极微光的应助被yasiraziz采纳,获得20
54秒前
炙热的万怨完成签到,获得积分10
55秒前
1分钟前
飞天大南瓜完成签到,获得积分10
1分钟前
求求了给篇文献完成签到,获得积分10
1分钟前
美好傲蕾完成签到,获得积分10
1分钟前
顺利毛豆完成签到,获得积分10
1分钟前
丰富广缘完成签到,获得积分10
1分钟前
忘乎所以完成签到,获得积分10
1分钟前
yan完成签到,获得积分10
1分钟前
mycn完成签到,获得积分10
1分钟前
zheng完成签到,获得积分10
1分钟前
美满尔蓝完成签到,获得积分10
1分钟前
温暖友易完成签到,获得积分10
1分钟前
舒适的妍完成签到,获得积分10
1分钟前
能毕业就行完成签到,获得积分10
1分钟前
陈微完成签到,获得积分10
1分钟前
愤怒的衬衫完成签到,获得积分10
1分钟前
falling_learning完成签到 ,获得积分10
1分钟前
鱼鱼完成签到 ,获得积分10
1分钟前
沐雨汐完成签到,获得积分10
1分钟前
爱学习完成签到,获得积分10
1分钟前
苏苏完成签到,获得积分10
1分钟前
cloudy完成签到,获得积分10
1分钟前
腼腆的冰安完成签到,获得积分10
1分钟前
无情捕完成签到,获得积分10
1分钟前
徐博完成签到,获得积分10
1分钟前
科研绿老头完成签到,获得积分10
2分钟前
背锅王船长完成签到,获得积分10
2分钟前
完美梦之完成签到,获得积分10
2分钟前
教育邮箱完成签到,获得积分10
2分钟前
dingyushu完成签到,获得积分10
2分钟前
Hdx完成签到,获得积分10
2分钟前
高大的嚓茶完成签到 ,获得积分10
2分钟前
ZF完成签到,获得积分10
2分钟前
周新哲完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190148
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852224
捐赠科研通 7788492
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560043
邀请新用户注册赠送积分活动 2482880